REmote MOnitoring of paTiEnts witH pacEmaker or implAntable cardioverteR defibrillaTor

Last updated: December 7, 2023
Sponsor: Semmelweis University Heart and Vascular Center
Overall Status: Active - Recruiting

Phase

N/A

Condition

Congestive Heart Failure

Chest Pain

Heart Failure

Treatment

Remote monitoring

Clinical Study ID

NCT06173089
4279-1/2022
  • Ages 18-100
  • All Genders

Study Summary

However, the current guidelines recommend the use of remote monitoring (RM) in patients with cardiac implantable electronic devices (CIED) to reduce inappropriate shocks or early detection of atrial fibrillation, data is incomprehensive on the effectiveness of decreasing heart failure events or mortality in patients with heart failure and reduced ejection fraction (HFrEF). The only randomized trial, which proved the efficacy of RM on mortality was the IN-TIME trial, which used a strict protocol for detection and intervention of the heart failure events.

The primary aim of this study is to optimize the use of remote monitoring system in HFrEF patients already implanted an implantable cardiac defibrillator (ICD) or a cardiac resynchronization therapy (CRT). By creating a high-quality system with structured safety-net, which is able to use the data of remote monitoring messages and alerts of our patients, we can improve their outcome. The primary endpoint is the non-fatal heart failure event or all-cause mortality. Secondary outcomes include all-cause mortality, cardiovascular mortality, heart failure hospitalization, cardiovascular hospitalization, unscheduled visits, af burden, stroke, inappropriate shocks, quality of life, NYHA functional class.

By using artificial intelligence-based methods, the optimal cut-off values of the previously, empirically used alert parameters will be validated or challenged. Additionally, cost-effectiveness to reduce the hospitalizations will be calculated.

Due to this remote monitoring structured safety-net, these patients with severe heart failure can be treated more efficiently, safely and cost-effectively.

Eligibility Criteria

Inclusion

Inclusion Criteria:

  1. CRT-P/CRT-D patients with a feasible device for home monitoring
  2. ICD (VVI/VDD/DDD) patients with a feasible device for home monitoring
  3. SR/AFib
  4. Transmission performance >80% in the first 2 weeks with new device
  5. Informed consent

Exclusion

Exclusion Criteria:

  1. Life expectancy<1 year
  2. Unable to transmit data
  3. Patient is unable to visit the physician/clinic in 12 hours when it is indicated bythe alerts
  4. Expected non-compliance
  5. Pregnancy
  6. Known drug, alcohol abuse
  7. Participation in other study or HM system concept

Study Design

Total Participants: 800
Treatment Group(s): 1
Primary Treatment: Remote monitoring
Phase:
Study Start date:
January 30, 2023
Estimated Completion Date:
August 30, 2025

Connect with a study center

  • Semmelweis University - Heart and Vascular Center

    Budapest, 1122
    Hungary

    Active - Recruiting

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.